Personalized Anemia Treatment Systems

This inventive concept envisions a next-generation approach to anemia treatment, integrating advanced technologies such as wearable devices, genomics, gene editing, and machine learning to provide personalized and optimized treatment outcomes.

The original patent disclosed compositions and methods for treating anemia using HIF prolyl hydroxylase inhibitors. However, these methods have limitations in terms of efficacy, dosing, and patient variability. The present inventive concept addresses these limitations by introducing a systems-based approach that leverages real-time physiological data, genomic analysis, and machine learning algorithms to tailor treatment to individual patients.

The inventive concept comprises a wearable device that monitors physiological data such as hemoglobin levels, blood oxygenation, and other vital signs. This data is analyzed in real-time using machine learning algorithms to adjust the dosage of a HIF prolyl hydroxylase inhibitor, ensuring optimal treatment outcomes. Additionally, the system incorporates genomic analysis to identify genetic markers associated with responsiveness to HIF prolyl hydroxylase inhibitors, allowing for personalized treatment regimens. Furthermore, the system can be combined with gene editing agents to modify the expression of genes involved in erythropoiesis, enhancing the efficacy of the HIF prolyl hydroxylase inhibitor.

The present inventive concept is novel and non-obvious in its integration of wearable devices, genomics, gene editing, and machine learning to provide personalized anemia treatment. The use of real-time physiological data and genomic analysis to adjust treatment dosages and regimens represents a significant departure from the original patent's methods, which relied on fixed dosing regimens and did not account for individual patient variability.

Alternative embodiments of the inventive concept could include the use of implantable devices, mobile apps, or cloud-based platforms to monitor and analyze patient data. The system could also be adapted for use in other disease areas, such as cancer or inflammatory disorders, where HIF prolyl hydroxylase inhibitors have therapeutic potential.

The present inventive concept has significant commercial potential in the anemia treatment market, which is projected to reach $15 billion by 2025. The system's ability to provide personalized and optimized treatment outcomes could lead to improved patient outcomes, reduced healthcare costs, and increased market share for pharmaceutical companies and healthcare providers.